25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

TVRD (Tvardi Therapeutics, Inc.) Stock Analysis
Buy, Hold or Sell?

Let's analyze Tvardi Therapeutics, Inc. together

I guess you are interested in Tvardi Therapeutics, Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Tvardi Therapeutics, Inc.’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Tvardi Therapeutics, Inc.’s Price Targets

I'm going to help you getting a better view of Tvardi Therapeutics, Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Tvardi Therapeutics, Inc.

I send you an email if I find something interesting about Tvardi Therapeutics, Inc..

1. Quick Overview

1.1. Quick analysis of Tvardi Therapeutics, Inc. (30 sec.)










1.2. What can you expect buying and holding a share of Tvardi Therapeutics, Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.52
Expected worth in 1 year
$5.80
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$2.28
Return On Investment
56.5%

For what price can you sell your share?

Current Price per Share
$4.03
Expected price per share
$3.85 - $8.64
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Tvardi Therapeutics, Inc. (5 min.)




Live pricePrice per Share (EOD)
$4.03

2.2. Growth of Tvardi Therapeutics, Inc. (5 min.)




Is Tvardi Therapeutics, Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$32.9m$16.2m-$30.8m-211.6%

How much money is Tvardi Therapeutics, Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$5.2m-$20.7m$15.5m297.7%
Net Profit Margin-301.7%-1,044.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Tvardi Therapeutics, Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Tvardi Therapeutics, Inc.?

Welcome investor! Tvardi Therapeutics, Inc.'s management wants to use your money to grow the business. In return you get a share of Tvardi Therapeutics, Inc..

First you should know what it really means to hold a share of Tvardi Therapeutics, Inc.. And how you can make/lose money.

Speculation

The Price per Share of Tvardi Therapeutics, Inc. is $4.03. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Tvardi Therapeutics, Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Tvardi Therapeutics, Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.52. Based on the TTM, the Book Value Change Per Share is $0.57 per quarter. Based on the YOY, the Book Value Change Per Share is $0.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Tvardi Therapeutics, Inc..

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.4511.0%-0.56-13.8%-2.22-55.1%-1.39-34.5%-1.39-34.5%-1.39-34.5%
Usd Book Value Change Per Share4.38108.7%0.5714.1%0.317.7%0.4410.9%0.4410.9%0.4410.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share4.38108.7%0.5714.1%0.317.7%0.4410.9%0.4410.9%0.4410.9%
Usd Price Per Share23.33-8.71-0.90-4.80-4.80-4.80-
Price to Earnings Ratio13.10-2.19--0.16-1.02-1.02-1.02-
Price-to-Total Gains Ratio5.33--1.89-0.02--0.93--0.93--0.93-
Price to Book Ratio6.63--2.94-0.14--1.40--1.40--1.40-
Price-to-Total Gains Ratio5.33--1.89-0.02--0.93--0.93--0.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.03
Number of shares248
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.570.44
Usd Total Gains Per Share0.570.44
Gains per Quarter (248 shares)141.27109.04
Gains per Year (248 shares)565.07436.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105655550436426
20113011200872862
3016951685013091298
4022602250017451734
5028252815021812170
6033903380026172606
7039563945030533042
8045214510034893478
9050865075039263914
10056515640043624350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.07.00.012.5%1.07.00.012.5%1.07.00.012.5%1.07.00.012.5%
Book Value Change Per Share2.02.00.050.0%4.04.00.050.0%4.04.00.050.0%4.04.00.050.0%4.04.00.050.0%
Dividend per Share0.00.04.00.0%0.00.08.00.0%0.00.08.00.0%0.00.08.00.0%0.00.08.00.0%
Total Gains per Share2.02.00.050.0%4.04.00.050.0%4.04.00.050.0%4.04.00.050.0%4.04.00.050.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Tvardi Therapeutics, Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.3800.570+669%0.310+1314%0.440+896%0.440+896%0.440+896%
Book Value Per Share--3.518-1.555+144%1.736+103%0.090+3807%0.090+3807%0.090+3807%
Current Ratio--4.03912.393-67%5.586-28%8.990-55%8.990-55%8.990-55%
Debt To Asset Ratio--0.2472.458-90%1.266-80%1.862-87%1.862-87%1.862-87%
Debt To Equity Ratio--0.3290.082+300%1.905-83%0.994-67%0.994-67%0.994-67%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--248560797.00062823356.300+296%5481497.975+4435%34152427.138+628%34152427.138+628%34152427.138+628%
Eps--0.445-0.558+225%-2.219+599%-1.389+412%-1.389+412%-1.389+412%
Ev To Ebitda Ratio---7.044-2.888-59%0.933-855%-0.977-86%-0.977-86%-0.977-86%
Free Cash Flow Per Share---0.947-0.844-11%-1.860+96%-1.352+43%-1.352+43%-1.352+43%
Free Cash Flow To Equity Per Share--1.405-0.290+121%-0.891+163%-0.591+142%-0.591+142%-0.591+142%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Market Cap37724427.000-479%218389797.00081505356.300+168%8403747.975+2499%44954552.138+386%44954552.138+386%44954552.138+386%
Net Profit Margin----3.0170%-10.4460%-6.7320%-6.7320%-6.7320%
Operating Margin----2.2920%-9.6490%-5.9700%-5.9700%-5.9700%
Operating Ratio---2.630-100%10.244-100%6.437-100%6.437-100%6.437-100%
Pb Ratio1.146-479%6.633-2.939+144%0.141+4591%-1.399+121%-1.399+121%-1.399+121%
Pe Ratio2.263-479%13.1022.190+498%-0.160+101%1.015+1191%1.015+1191%1.015+1191%
Price Per Share4.030-479%23.3308.707+168%0.898+2499%4.802+386%4.802+386%4.802+386%
Price To Free Cash Flow Ratio-1.064+83%-6.159-3.070-50%-0.154-98%-1.612-74%-1.612-74%-1.612-74%
Price To Total Gains Ratio0.920-479%5.327-1.892+136%0.024+21954%-0.934+118%-0.934+118%-0.934+118%
Quick Ratio--5.74512.385-54%9.646-40%11.015-48%11.015-48%11.015-48%
Return On Assets--0.095-0.301+416%-0.255+368%-0.278+392%-0.278+392%-0.278+392%
Return On Equity--0.1270.032+300%-0.771+709%-0.370+392%-0.370+392%-0.370+392%
Total Gains Per Share--4.3800.570+669%0.310+1314%0.440+896%0.440+896%0.440+896%
Usd Book Value--32927000.000-14560500.000+144%16246250.000+103%842875.000+3807%842875.000+3807%842875.000+3807%
Usd Book Value Change Per Share--4.3800.570+669%0.310+1314%0.440+896%0.440+896%0.440+896%
Usd Book Value Per Share--3.518-1.555+144%1.736+103%0.090+3807%0.090+3807%0.090+3807%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--248560797.00062823356.300+296%5481497.975+4435%34152427.138+628%34152427.138+628%34152427.138+628%
Usd Eps--0.445-0.558+225%-2.219+599%-1.389+412%-1.389+412%-1.389+412%
Usd Free Cash Flow---8865000.000-7896000.000-11%-17413250.000+96%-12654625.000+43%-12654625.000+43%-12654625.000+43%
Usd Free Cash Flow Per Share---0.947-0.844-11%-1.860+96%-1.352+43%-1.352+43%-1.352+43%
Usd Free Cash Flow To Equity Per Share--1.405-0.290+121%-0.891+163%-0.591+142%-0.591+142%-0.591+142%
Usd Market Cap37724427.000-479%218389797.00081505356.300+168%8403747.975+2499%44954552.138+386%44954552.138+386%44954552.138+386%
Usd Price Per Share4.030-479%23.3308.707+168%0.898+2499%4.802+386%4.802+386%4.802+386%
Usd Profit--4167000.000-5223500.000+225%-20773750.000+599%-12998625.000+412%-12998625.000+412%-12998625.000+412%
Usd Revenue---1645000.000-100%2749000.000-100%2197000.000-100%2197000.000-100%2197000.000-100%
Usd Total Gains Per Share--4.3800.570+669%0.310+1314%0.440+896%0.440+896%0.440+896%
 EOD+3 -5MRQTTM+23 -11YOY+27 -73Y+27 -75Y+27 -710Y+27 -7

3.3 Fundamental Score

Let's check the fundamental score of Tvardi Therapeutics, Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-152.263
Price to Book Ratio (EOD)Between0-11.146
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.745
Current Ratio (MRQ)Greater than14.039
Debt to Asset Ratio (MRQ)Less than10.247
Debt to Equity Ratio (MRQ)Less than10.329
Return on Equity (MRQ)Greater than0.150.127
Return on Assets (MRQ)Greater than0.050.095
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Tvardi Therapeutics, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5019.438
Ma 20Greater thanMa 504.638
Ma 50Greater thanMa 10021.092
Ma 100Greater thanMa 20023.419
OpenGreater thanClose4.080
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Fundamental data was last updated by Penke on 2025-10-29 01:40:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Tvardi Therapeutics, Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Tvardi Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-301.7%+301.7%
TTM-301.7%YOY-1,044.6%+742.9%
TTM-301.7%5Y-673.2%+371.5%
5Y-673.2%10Y-673.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--68.8%+68.8%
TTM-301.7%-160.2%-141.5%
YOY-1,044.6%-189.1%-855.5%
3Y-673.2%-262.3%-410.9%
5Y-673.2%-340.9%-332.3%
10Y-673.2%-469.0%-204.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Tvardi Therapeutics, Inc. is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Tvardi Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • 9.5% Return on Assets means thatΒ Tvardi Therapeutics, Inc. generatedΒ $0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 9.5%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -30.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ9.5%TTM-30.1%+39.6%
TTM-30.1%YOY-25.5%-4.5%
TTM-30.1%5Y-27.8%-2.3%
5Y-27.8%10Y-27.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.5%-11.6%+21.1%
TTM-30.1%-11.4%-18.7%
YOY-25.5%-11.2%-14.3%
3Y-27.8%-12.0%-15.8%
5Y-27.8%-11.7%-16.1%
10Y-27.8%-13.7%-14.1%
4.3.1.3. Return on Equity

Shows how efficient Tvardi Therapeutics, Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Tvardi Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • 12.7% Return on Equity means Tvardi Therapeutics, Inc. generated $0.13Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 12.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 3.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ12.7%TTM3.2%+9.5%
TTM3.2%YOY-77.1%+80.2%
TTM3.2%5Y-37.0%+40.1%
5Y-37.0%10Y-37.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.7%-13.3%+26.0%
TTM3.2%-14.4%+17.6%
YOY-77.1%-15.0%-62.1%
3Y-37.0%-16.6%-20.4%
5Y-37.0%-16.7%-20.3%
10Y-37.0%-19.4%-17.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Tvardi Therapeutics, Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Tvardi Therapeutics, Inc. is operatingΒ .

  • Measures how much profit Tvardi Therapeutics, Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Tvardi Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-229.2%+229.2%
TTM-229.2%YOY-964.9%+735.7%
TTM-229.2%5Y-597.0%+367.8%
5Y-597.0%10Y-597.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--147.6%+147.6%
TTM-229.2%-254.7%+25.5%
YOY-964.9%-251.9%-713.0%
3Y-597.0%-248.0%-349.0%
5Y-597.0%-332.9%-264.1%
10Y-597.0%-499.4%-97.6%
4.3.2.2. Operating Ratio

Measures how efficient Tvardi Therapeutics, Inc. is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.630-2.630
TTM2.630YOY10.244-7.615
TTM2.6305Y6.437-3.807
5Y6.43710Y6.4370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.868-1.868
TTM2.6302.640-0.010
YOY10.2442.840+7.404
3Y6.4373.556+2.881
5Y6.4374.562+1.875
10Y6.4376.341+0.096
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Tvardi Therapeutics, Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Tvardi Therapeutics, Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 4.04Β means the company has $4.04 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 4.039. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.393. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.039TTM12.393-8.354
TTM12.393YOY5.586+6.807
TTM12.3935Y8.990+3.404
5Y8.99010Y8.9900.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0393.258+0.781
TTM12.3933.515+8.878
YOY5.5863.923+1.663
3Y8.9904.375+4.615
5Y8.9905.618+3.372
10Y8.9905.974+3.016
4.4.3.2. Quick Ratio

Measures if Tvardi Therapeutics, Inc. is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Tvardi Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • A Quick Ratio of 5.74Β means the company can pay off $5.74 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 5.745. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.385. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.745TTM12.385-6.640
TTM12.385YOY9.646+2.739
TTM12.3855Y11.015+1.369
5Y11.01510Y11.0150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.7452.711+3.034
TTM12.3853.130+9.255
YOY9.6463.786+5.860
3Y11.0154.322+6.693
5Y11.0155.648+5.367
10Y11.0156.351+4.664
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Tvardi Therapeutics, Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Tvardi Therapeutics, Inc.Β assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Tvardi Therapeutics, Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25Β means that Tvardi Therapeutics, Inc. assets areΒ financed with 24.7% credit (debt) and the remaining percentage (100% - 24.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 0.247. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 2.458. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ0.247TTM2.458-2.211
TTM2.458YOY1.266+1.192
TTM2.4585Y1.862+0.596
5Y1.86210Y1.8620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2470.355-0.108
TTM2.4580.364+2.094
YOY1.2660.334+0.932
3Y1.8620.353+1.509
5Y1.8620.350+1.512
10Y1.8620.380+1.482
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Tvardi Therapeutics, Inc. is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Tvardi Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 32.9% means that company has $0.33 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tvardi Therapeutics, Inc.:

  • The MRQ is 0.329. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.082. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.329TTM0.082+0.247
TTM0.082YOY1.905-1.823
TTM0.0825Y0.994-0.911
5Y0.99410Y0.9940.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3290.414-0.085
TTM0.0820.448-0.366
YOY1.9050.436+1.469
3Y0.9940.476+0.518
5Y0.9940.475+0.519
10Y0.9940.524+0.470
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Tvardi Therapeutics, Inc. generates.

  • Above 15 is considered overpriced butΒ always compareΒ Tvardi Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • A PE ratio of 13.10 means the investor is paying $13.10Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tvardi Therapeutics, Inc.:

  • The EOD is 2.263. Based on the earnings, the company is cheap. +2
  • The MRQ is 13.102. Based on the earnings, the company is underpriced. +1
  • The TTM is 2.190. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.263MRQ13.102-10.839
MRQ13.102TTM2.190+10.912
TTM2.190YOY-0.160+2.350
TTM2.1905Y1.015+1.175
5Y1.01510Y1.0150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.263-2.533+4.796
MRQ13.102-2.257+15.359
TTM2.190-2.644+4.834
YOY-0.160-3.661+3.501
3Y1.015-3.622+4.637
5Y1.015-5.767+6.782
10Y1.015-6.725+7.740
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Tvardi Therapeutics, Inc.:

  • The EOD is -1.064. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.159. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.070. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.064MRQ-6.159+5.095
MRQ-6.159TTM-3.070-3.088
TTM-3.070YOY-0.154-2.917
TTM-3.0705Y-1.612-1.458
5Y-1.61210Y-1.6120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.064-3.495+2.431
MRQ-6.159-2.975-3.184
TTM-3.070-3.684+0.614
YOY-0.154-4.286+4.132
3Y-1.612-5.353+3.741
5Y-1.612-8.219+6.607
10Y-1.612-9.692+8.080
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Tvardi Therapeutics, Inc. is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 6.63 means the investor is paying $6.63Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Tvardi Therapeutics, Inc.:

  • The EOD is 1.146. Based on the equity, the company is underpriced. +1
  • The MRQ is 6.633. Based on the equity, the company is overpriced. -1
  • The TTM is -2.939. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.146MRQ6.633-5.487
MRQ6.633TTM-2.939+9.572
TTM-2.939YOY0.141-3.080
TTM-2.9395Y-1.399-1.540
5Y-1.39910Y-1.3990.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1462.361-1.215
MRQ6.6332.125+4.508
TTM-2.9392.174-5.113
YOY0.1412.566-2.425
3Y-1.3992.665-4.064
5Y-1.3993.754-5.153
10Y-1.3994.338-5.737
4.6.2. Total Gains per Share

2.4. Latest News of Tvardi Therapeutics, Inc.

Does Tvardi Therapeutics, Inc. still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Tvardi Therapeutics, Inc. to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-11-12
16:10
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law FirmRead
2025-11-09
15:18
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Income before Tax  -20,0167,540-12,4764,399-8,0773,171-4,9069,0734,167
Net Income  -20,0167,540-12,4764,797-7,6792,773-4,9069,0734,167
Gross Profit  9141,5692,483-1,0701,4131,1562,569-2,616-47



6.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. All numbers in thousands.

Summary
Total Assets43,750
Total Liabilities10,823
Total Stockholder Equity32,927
 As reported
Total Liabilities 10,823
Total Stockholder Equity+ 32,927
Total Assets = 43,750

Assets

Total Assets43,750
Total Current Assets43,130
Long-term Assets620
Total Current Assets
Cash And Cash Equivalents 20,648
Short-term Investments 20,346
Other Current Assets 2,136
Total Current Assets  (as reported)43,130
Total Current Assets  (calculated)43,130
+/-0
Long-term Assets
Property Plant Equipment 249
Intangible Assets 354
Long-term Assets Other 17
Long-term Assets  (as reported)620
Long-term Assets  (calculated)620
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,678
Long-term Liabilities145
Total Stockholder Equity32,927
Total Current Liabilities
Short-term Debt 109
Accounts payable 2,425
Other Current Liabilities 8,144
Total Current Liabilities  (as reported)10,678
Total Current Liabilities  (calculated)10,678
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt145
Long-term Liabilities  (as reported)145
Long-term Liabilities  (calculated)145
+/-0
Total Stockholder Equity
Common Stock9
Retained Earnings -97,648
Accumulated Other Comprehensive Income -13
Other Stockholders Equity 130,579
Total Stockholder Equity (as reported)32,927
Total Stockholder Equity (calculated)32,927
+/-0
Other
Capital Stock9
Cash and Short Term Investments 40,994
Common Stock Shares Outstanding 8,455
Liabilities and Stockholders Equity 43,750
Net Debt -20,394
Net Invested Capital 32,927
Net Working Capital 32,452
Property Plant and Equipment Gross 249
Short Long Term Debt Total 254



6.3. Balance Sheets Structured

All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30
> Total Assets 
115,338
27,001
90,099
72,495
12,514
43,827
38,947
43,750
43,75038,94743,82712,51472,49590,09927,001115,338
   > Total Current Assets 
100,603
26,158
81,225
63,859
10,703
43,827
38,947
43,130
43,13038,94743,82710,70363,85981,22526,158100,603
       Cash And Cash Equivalents 
63,283
22,919
46,996
49,239
9,438
37,903
34,217
20,648
20,64834,21737,9039,43849,23946,99622,91963,283
       Short-term Investments 
15,666
48,983
22,777
7,379
4,975
0
0
20,346
20,346004,9757,37922,77748,98315,666
       Net Receivables 
5,730
4,017
2,921
1,820
0
4,495
2,238
0
02,2384,49501,8202,9214,0175,730
       Inventory 
3,266
0
2,741
1,644
0
900
900
0
090090001,6442,74103,266
       Other Current Assets 
12,658
-778
5,790
3,777
1,265
529
1,592
2,136
2,1361,5925291,2653,7775,790-77812,658
   > Long-term Assets 
14,735
843
8,874
8,636
1,811
0
0
620
620001,8118,6368,87484314,735
       Property Plant Equipment 
8,488
378
7,374
7,136
310
0
0
249
249003107,1367,3743788,488
       Intangible Assets 
0
448
0
0
401
0
0
354
35400401004480
> Total Liabilities 
29,696
89,059
60,296
60,897
91,017
48,420
47,020
10,823
10,82347,02048,42091,01760,89760,29689,05929,696
   > Total Current Liabilities 
22,881
3,281
15,095
13,901
5,307
3,972
1,199
10,678
10,6781,1993,9725,30713,90115,0953,28122,881
       Short-term Debt 
497
93
220
168
92
0
0
109
109009216822093497
       Accounts payable 
7,978
1,611
4,978
6,755
1,978
1,434
4
2,425
2,42541,4341,9786,7554,9781,6117,978
       Other Current Liabilities 
14,406
1,577
9,897
6,978
3,237
2,538
1,195
8,144
8,1441,1952,5383,2376,9789,8971,57714,406
   > Long-term Liabilities 
6,815
85,778
45,201
46,996
85,710
44,448
45,821
145
14545,82144,44885,71046,99645,20185,7786,815
> Total Stockholder Equity
85,642
-62,058
29,803
11,598
-78,503
-4,593
-8,073
32,927
32,927-8,073-4,593-78,50311,59829,803-62,05885,642
   Common Stock
54
19
54
54
19
5
2
9
9251954541954
   Retained Earnings -97,648-760,518-755,612-79,529-735,457-715,441-62,839-652,408
   Accumulated Other Comprehensive Income -13000-121-1910-439
   Capital Surplus 00000000
   Treasury Stock00000000
   Other Stockholders Equity 
738,435
762
745,381
747,122
1,007
751,014
752,443
130,579
130,579752,443751,0141,007747,122745,381762738,435



6.4. Balance Sheets

All numbers in thousands.




6.5. Cash Flows

All numbers in thousands.




6.6. Income Statements

All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. All numbers in thousands.

Gross Profit (+$)
totalRevenue7,137
Cost of Revenue-812
Gross Profit6,3256,325
 
Operating Income (+$)
Gross Profit6,325
Operating Expense-62,106
Operating Income-55,781-55,781
 
Operating Expense (+$)
Research Development32,755
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense62,10632,755
 
Net Interest Income (+$)
Interest Income0
Interest Expense-8,473
Other Finance Cost-8,473
Net Interest Income0
 
Pretax Income (+$)
Operating Income-55,781
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-71,265-40,297
EBIT - interestExpense = -71,265
-71,265
-62,394
Interest Expense8,473
Earnings Before Interest and Taxes (EBIT)-62,792-62,792
Earnings Before Interest and Taxes (EBITDA)-62,600
 
After tax Income (+$)
Income Before Tax-71,265
Tax Provision-0
Net Income From Continuing Ops0-71,265
Net Income-70,867
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses62,918
Total Other Income/Expenses Net-15,4840
 

Technical Analysis of Tvardi Therapeutics, Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Tvardi Therapeutics, Inc.. The general trend of Tvardi Therapeutics, Inc. is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Tvardi Therapeutics, Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Tvardi Therapeutics, Inc. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Tvardi Therapeutics, Inc..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.65 < 8.136 < 8.64.

The bearish price targets are: 3.85.

Know someone who trades $TVRD? Share this with them.πŸ‘‡

Tvardi Therapeutics, Inc. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Tvardi Therapeutics, Inc.. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Tvardi Therapeutics, Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Tvardi Therapeutics, Inc.. The current macd is -4.47135233.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Tvardi Therapeutics, Inc. price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Tvardi Therapeutics, Inc.. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Tvardi Therapeutics, Inc. price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Tvardi Therapeutics, Inc. Daily Moving Average Convergence/Divergence (MACD) ChartTvardi Therapeutics, Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Tvardi Therapeutics, Inc.. The current adx is 57.34.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Tvardi Therapeutics, Inc. shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Tvardi Therapeutics, Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Tvardi Therapeutics, Inc.. The current sar is 6.18501809.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Tvardi Therapeutics, Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Tvardi Therapeutics, Inc.. The current rsi is 19.44. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Tvardi Therapeutics, Inc. Daily Relative Strength Index (RSI) ChartTvardi Therapeutics, Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Tvardi Therapeutics, Inc.. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Tvardi Therapeutics, Inc. price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Tvardi Therapeutics, Inc. Daily Stochastic Oscillator ChartTvardi Therapeutics, Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Tvardi Therapeutics, Inc.. The current cci is -79.83776933.

Tvardi Therapeutics, Inc. Daily Commodity Channel Index (CCI) ChartTvardi Therapeutics, Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Tvardi Therapeutics, Inc.. The current cmo is -67.70672401.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Tvardi Therapeutics, Inc. Daily Chande Momentum Oscillator (CMO) ChartTvardi Therapeutics, Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Tvardi Therapeutics, Inc.. The current willr is -84.34782609.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Tvardi Therapeutics, Inc. Daily Williams %R ChartTvardi Therapeutics, Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Tvardi Therapeutics, Inc..

Tvardi Therapeutics, Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Tvardi Therapeutics, Inc.. The current atr is 1.1811577.

Tvardi Therapeutics, Inc. Daily Average True Range (ATR) ChartTvardi Therapeutics, Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Tvardi Therapeutics, Inc.. The current obv is -8,324,782.

Tvardi Therapeutics, Inc. Daily On-Balance Volume (OBV) ChartTvardi Therapeutics, Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Tvardi Therapeutics, Inc.. The current mfi is 9.74824044.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Tvardi Therapeutics, Inc. Daily Money Flow Index (MFI) ChartTvardi Therapeutics, Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Tvardi Therapeutics, Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-08-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-02MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-09-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-09-11STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-10-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-10-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-11-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-11-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Tvardi Therapeutics, Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Tvardi Therapeutics, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5019.438
Ma 20Greater thanMa 504.638
Ma 50Greater thanMa 10021.092
Ma 100Greater thanMa 20023.419
OpenGreater thanClose4.080
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Tvardi Therapeutics, Inc. with someone you think should read this too:
  • Are you bullish or bearish on Tvardi Therapeutics, Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Tvardi Therapeutics, Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Tvardi Therapeutics, Inc.

I send you an email if I find something interesting about Tvardi Therapeutics, Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Tvardi Therapeutics, Inc..

Receive notifications about Tvardi Therapeutics, Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.